Trial Profile
Phase 2 trial to determine the efficacy, safety, and feasibility of alternating osimertinib with gefitinib in patients with EGFR-T790M mutation positive advanced non-small cell lung cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms OSCILLATE
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer
- 04 Feb 2020 Status changed from recruiting to active, no longer recruiting.
- 10 Mar 2018 Status changed from not yet recruiting to recruiting.